TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05318950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-learning
Description: 8 lessons about nutrition and lifestyle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-learning
Description: 8 lessons about nutrition and lifestyle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-learning
Description: 8 lessons about nutrition and lifestyle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
Study: NCT03337217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position during colonoscopy
Description: Position during colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Position during colonoscopy
Description: Position during colonoscopy
Study: NCT00606138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: One 0.5 mg intravitreal injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: panretinal photocoagulation (up to 500 300-500 um laser spots)
Study: NCT01935479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-10-T
Description: subcutaneous administration of teriparatide acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-10-T
Description: subcutaneous administration of teriparatide acetate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo AK159
Study: NCT04573296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitadio
Description: A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional high-intensity lifestyle intervention program
Description: A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
Study: NCT03294616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electroacupuncture
Description: Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electroacupuncture
Description: Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electroacupuncture
Description: Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
Study: NCT02536469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-IL8
Description: HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
Study: NCT04334928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil
Description: Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil
Description: Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo: Emtricitabine/tenofovir disoproxil Placebo
Description: Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Emtricitabine/tenofovir disoproxil Placebo
Description: Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo: Hydroxychloroquine
Description: Placebo: Tablets similar in appearance to Hydroxychloroquine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Hydroxychloroquine
Description: Placebo: Tablets similar in appearance to Hydroxychloroquine
Study: NCT03489226

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsimax
Description: Capsimax

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsimax
Description: Capsimax

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal
Description: Meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Meal
Description: Meal
Study: NCT01350934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)
Description: one combination tablet once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: 0.25 μg once daily orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium 500 mg
Description: one 500 mg tablet once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium 500 mg
Description: one 500 mg tablet once daily
Study: NCT01027676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study treatment
Description: Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks
Study: NCT00931281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: capsules, QD or BID, 14 days, ascending doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: capsules, QD or BID, 14 days, ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-450
Description: capsule, QD or BID, 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ritonavir
Description: capsule, QD or BID, 14 days
Study: NCT03226691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
Study: NCT01331590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Study: NCT05547035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient follow-up of depression
Description: All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~* assess the depression severity by using MADRS scale~* assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~* the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression.
Study: NCT03484104

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of tissue oxygenation index (TOI)
Description: TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
Study: NCT01511302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60, 2ml, nebulized twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60, 2ml, nebulized twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline placebo, 2 ml, nebulized twice daily.
Study: NCT00093080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
Study: NCT01023399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate + Amodiaquine
Description: Artesunate + Amodiaquine fixed dose combination
Study: NCT01511302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
Study: NCT00415636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC83/LY2603618
Description: 40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC83/LY2603618
Description: 40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC83/LY2603618
Description: 70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC83/LY2603618
Description: 105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC83/LY2603618
Description: 150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC83/LY2603618
Description: 195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
Study: NCT01910454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)
Description: The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task Specific Training (TST)
Description: The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
Study: NCT02328495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Filling
Description: Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used.
Study: NCT04507204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adhansia XR
Description: Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
Study: NCT04997850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib + sindilimab/carrelizumab
Description: 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor.
Study: NCT01162759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring
Description: Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
Study: NCT02285881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making
Description: In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
Study: NCT03301584

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced collaboration to promote patient participation
Description: Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care treatment
Description: The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
Study: NCT02666053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study: NCT00539656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo expansion of cord blood
Description: Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
Study: NCT03862560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training program
Description: Strength training program in female soccer players